Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.
about
Brivaracetam add-on therapy for epilepsyEpilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewProfile of brivaracetam and its potential in the treatment of epilepsyBrivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base[Brivaracetam for add-on treatment in focal epilepsy].Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neuronsPerspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Emerging drugs for partial-onset epilepsy: a review of brivaracetamEfficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.New developments in the management of partial-onset epilepsy: role of brivaracetam.Brivaracetam for the treatment of epilepsy in adults.Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.Evaluation of brivaracetam: a new drug to treat epilepsy.Brivaracetam for the treatment of epilepsy.Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Brivaracetam: First Global Approval.Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures.Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures.Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.Stereochemistry of the Brivaracetam Diastereoisomers.Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial.Brivaracetam disposition in mild to severe hepatic impairment.Effect of brivaracetam on CYP3A activity, measured by oral midazolam.Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.Drug development: Illuminated targets.Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.Brivaracetam: a novel antiepileptic drug for focal-onset seizures.A review of the pharmacology and clinical efficacy of brivaracetam.Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.Brivaracetam in the Treatment of Patients with Epilepsy-First Clinical Experiences.Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
P2860
Q24188269-FE7D7F9F-FD51-4779-8885-C785F41FD1C0Q26743786-FADCE31C-B4B0-4508-8EB1-D3C239B29C6CQ26776317-5661BC7C-ADE8-4E08-A664-7CF2EFA2A9FDQ28076065-ABFB6B13-C015-42CE-B3EC-930AA2D61423Q30390285-CD3DEC9B-9AFE-4F86-91B0-E1F026B2BAC8Q30627739-C36C5284-7AAE-4AFD-AF56-F101B66D22D1Q35761335-402A1912-60CC-462A-9CE3-337D7F65ACA5Q36891212-3F2D8E54-CD8E-4AB8-A743-76AA66D53BA4Q37113376-2526D1B4-D456-4462-961B-EC0F980150D2Q37693757-774BEF5C-14F3-458E-BADE-53EB5D313349Q38195636-6C543E8E-93E7-42CB-9122-50BB50947FAFQ38199973-FD827237-FBE0-4AC5-97F9-C0FD3FFBACF8Q38614499-486F249F-41F1-4FCE-A203-60B88D4F2BC0Q38621010-A76AD920-7401-4C85-87AC-2108AFD1A497Q38626838-CC166206-CF58-4CDE-881F-895D9485DED2Q38652806-3B7810C8-DA6C-4B01-A50F-0219731AAEE2Q38694479-7BA31B92-2C99-46EE-B56B-634212A2C9ADQ38739649-D165BE8F-87B9-43F5-B12B-AD1F6E38903BQ38743281-03D2A181-F133-43D9-9CA0-2E6CAE8D32D2Q38752407-10DD2513-7491-4072-A433-F239ECF4B53EQ38844513-C5D4F4B7-F84A-4EDB-AB75-9248621CF516Q38915714-67503050-FBDF-48E0-B7EC-38191EFCB078Q38922348-D9CAC763-C1C6-4A08-8C0F-494A3E50310EQ38985697-2B217768-14FB-405A-9583-D17BCFD1B1A4Q39707630-48F7A403-90F9-4EB1-9EF4-855FA8DEF89DQ39794501-E6439F5D-E206-4D7F-8453-A7B56B092E0AQ40134330-FCF14685-ADC3-45C2-BC93-AF667E03B9FAQ41877287-4123FD4D-8367-4CC2-ACE3-3378E72083ECQ44231616-225A844C-F28F-414F-8B3C-182660FE59C2Q47774665-334ECF1E-324D-4626-B33B-9F75D2957AE2Q47836472-1C30EA7E-8803-4F68-9BAF-9D9519FA3DECQ47853821-4ADF45B7-F973-4226-9CC9-2F7181F49427Q47926989-1866D20B-3E65-408D-BCB6-7176D0459605Q48070946-34DDFFAB-A7FD-41A9-87BE-6140ABB8FFAFQ48130509-59BF2BEF-F360-49E6-AB1A-D1088AF73EB1Q49253776-4E5B2912-F999-428D-A16B-70F1A3C73C0AQ49700507-554AB618-B397-41DF-BBCA-B53D12D66A27Q50075643-0B66A17A-E0B2-4E7B-9407-23B1C0390AFAQ50183085-C9CD92DD-55DD-467A-B44F-51570A93FE2DQ51771465-9C369F17-C39E-4C13-83B7-1742500F66F6
P2860
Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Efficacy and tolerability of a ...... randomized, controlled trial.
@en
Efficacy and tolerability of a ...... randomized, controlled trial.
@nl
type
label
Efficacy and tolerability of a ...... randomized, controlled trial.
@en
Efficacy and tolerability of a ...... randomized, controlled trial.
@nl
prefLabel
Efficacy and tolerability of a ...... randomized, controlled trial.
@en
Efficacy and tolerability of a ...... randomized, controlled trial.
@nl
P2093
P2860
P1433
P1476
Efficacy and tolerability of a ...... randomized, controlled trial.
@en
P2093
Edouard Hirsch
Martin Johnson
Ursula Falter
Wim Van Paesschen
P2860
P356
10.1111/J.1528-1167.2012.03598.X
P577
2012-07-19T00:00:00Z